Apellis Pharmaceuticals Inc.
Apellis Pharmaceuticals Announces Preliminary 2024 Revenues and Key Executive Changes
Summary
Apellis Pharmaceuticals, Inc. announced preliminary unaudited U.S. net product revenues for 2024, with SYFOVRE contributing $611 million and EMPAVELI contributing $98 million. The company also reported a strong financial position with year-end cash of approximately $410 million. Additionally, the company announced the departure of Chief Operating Officer Adam Townsend and the appointment of Keli Walbert to the Board of Directors.
Profitelligence Alerts
Get alerts for APLS
Be first to know when Apellis Pharmaceuticals Inc. files with the SEC.
Filing Categories
Exhibits (1)
Advertisement
About Apellis Pharmaceuticals Inc.
Apellis Pharmaceuticals Inc. is a biopharmaceutical company dedicated to developing novel therapeutic compounds to address complement-mediated diseases. The primary focus of Apellis is to pioneer medicines leveraging targeted inhibition of the complement system, a key component of the immune system that plays a crucial role in a variety of diseases. The company's flagship product, targeting diseases such as geographic atrophy and paroxysmal nocturnal hemoglobinuria (PNH), highlights its commitment to addressing unmet medical needs with innovative treatments. Apellis Pharmaceuticals operates in the highly competitive pharmaceutical and biotechnology industry, collaborating with healthcare providers and research institutions to advance clinical treatment options. Headquartered in Waltham, Massachusetts, its contributions to medical science are significant, paving the way for advancements in immunology and therapy development. As a publicly traded entity, Apellis influences the healthcare sector by enhancing treatment paradigms and offering new hope for patients with chronic and debilitating conditions.
Official SEC Documents
Advertisement